Overview of the Market
In 2023, the market for active implantable CDMOs and catheters was estimated to be worth USD 6.92 billion. With a compound annual growth rate (CAGR) of 10.82% from 2024 to 2032, the sector is expected to increase from USD 7.49 billion in 2024 to USD 18.8 billion by 2032.

The market is growing because of more manufacturing outsourcing and growing strategic initiatives related to catheters and active implantable CDMO.

The global market for catheters and active implanted CDMOs is expanding significantly because of growing initiatives that are fostering innovation and enhancing market accessibility. Strategic mergers and acquisitions enable companies to offer comprehensive solutions and accelerate product development by combining resources and expertise. At the same time, increased investments in healthcare infrastructure, especially in emerging nations, and a growing need for minimally invasive procedures are driving up the usage of advanced catheters and implantable devices.

Perspectives on Market Segments

  • The Catheters and Active Implantable CDMO Market has been divided into three segments based on the service segment: endoscopy devices, active implantable devices, and catheters.
  • The Catheters and Active Implantable CDMO Market is divided into government organizations, academic and research institutions, and medical device OEM firms based on the end user.


Regional Perspectives

  • In 2023, North America held the biggest market share, which it is expected to maintain throughout the forecast period. Nonetheless, over the course of the forecast period, Asia-Pacific is anticipated to develop at the greatest CAGR.
  • The market for active implantable CDMOs in North America is expanding rapidly due to a favorable regulatory environment, growing healthcare demands, and technology breakthroughs. Furthermore, the market is driven by advanced healthcare infrastructure and significant research & development spending that makes it possible to create innovative implantable devices. Additionally, there are growth prospects due to the rise of customized treatment, the need for minimally invasive solutions, and prospects for expansion into new countries.
  • Europe, which is further divided into Germany, France, the United Kingdom, Italy, Spain, and the Rest of Europe, comes after the Americas. The market for active implantable CDMOs in Europe has a lot of room to grow thanks to increased healthcare demands and technology developments. The need for specialized manufacturing knowledge is being driven by technological improvements in implantable devices, including insulin pumps, neurostimulators, and next-generation cardiac pacemakers. The need for advanced, superior implanted solutions is further increased by the aging population and the rising incidence of chronic diseases.
  • Over the course of the forecast period, Asia-Pacific is anticipated to expand at the fastest rate and see substantial expansion due to several important variables. The need for advanced implantable devices is being driven by the quick development of medical technology and rising investments in healthcare infrastructure in nations like China, India, and Japan. The need for creative solutions is further fueled by the aging population, diabetes, and the increasing prevalence of chronic diseases.


Key Players
Integer Holdings Corporation (US), Cirtec (US), Biomerics (US), Switchback Medical (US), Velentium LLC (US), Heraeus Group (Germany), Zeus Company LLC (US), Veranex (US), Freudenberg Medical (US), and Medeologix (Taiwan) are the leading companies in the catheter and active implantable CDMO market.